---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-081417"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:16:33.953517+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports positive Phase 2 results for ANEB-001 reversing THC effects

## Summary
- Low 10 mg dose of ANEB-001 given 1 hour after THC rapidly reversed psychotropic effects (VAS feeling high p<0.0001).
- Pre-specified pooled analysis at 21/30 mg THC showed significance on all primary outcomes (p<0.02 for each).
- ANEB-001 was well tolerated; no serious adverse events; mild to moderate THC symptoms observed before dosing.
- High-fat meal blunted THC effects, but 10 mg ANEB-001 still significantly reduced VAS feeling high (p=0.003).
- Company expects End of Phase 2A meeting with FDA by mid-2023 to discuss path forward.

## SEC filing metadata
- accession: 0001193125-23-081417
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000119312523081417/0001193125-23-081417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000119312523081417/d483501d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-081417
- JSON: https://secwatch.observer/filing/0001193125-23-081417.json
- Plain text: https://secwatch.observer/filing/0001193125-23-081417.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.